Eighty-four patients with typical chronic lymphocytic leukemia 27% of patients with B-CLL. [11] [12] [13] Fegan et al 13 
Birmingham Heartland's Hospital. All had been followed-up since diagnosis at these clinics. Cytogenetic studies took place between 1989 and 1994. The clinical status of the patients Introduction was censored in June 1996.
Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias in the Western world and accounts for over Patients 40% of all leukemia cases. Prognosis has been related to age, sex and Binet/Rai stage. Between 55 and 65% of all patients The patients' records were examined and the Binet stage was with CLL have chromosomal abnormalities as detected by noted at diagnosis and any change was documented. Treatcytogenetic analysis 1,2 but few centres perform routine cytogments for CLL were also recorded as were the causes of death. enetic analysis because of the perception that limited prognos-A patient was considered to have had a CLL-related death if tic information can be gained over and above that of the he/she died as a result of cytopenias, high-grade lymphoma Binet/Rai staging. The presence of a clonal abnormality, howor infection; also if CLL was quoted as the cause of death on ever, may be an aid in the diagnosis and assessment of progthe death certificate. Otherwise death was considered nonnosis. Deletions at 13q14 are the most frequent abnormality CLL related. In all cases survival was assessed from diagnosis. in CLL and occur in up to 30% of patients. Cytogenetic analysis be more common than previously thought, occurring in 14-This was performed on peripheral blood as previously described. 13 Briefly, cultures were incubated in the presence
Statistics
Survival was analysed by the method of Kaplan and Meier and the Mantel Haenszel test. Fisher's exact test and MannWhitney tests were also utilised.
Results
The mean age of the 84 patients was 60 years, range 37-89. The male:female ratio was 1.9. An abnormal karyotype was present in 43 patients (51%). There was no significant difference between the Birmingham and Cardiff cohorts with abnormalities and survival. There was, however, significantly longer follow-up of the Cardiff cohort (median 123 months vs 75 months). Deletions or translocations involving 13q14 were ease progression occurred in 10 of the 11 patients with deletions at 11q, nine A to C and one B to C. Patients without the commonest abnormalities, present in 14 (16%) patients, deletions of 11q were detected in 11 (13%) patients and 11q deletions showed progression in 15 cases (20%) (A to B in seven, B to C in six and A to C in two). The increased deletions of 6q were seen in five (6%) patients. Only two patients had trisomy 12. Complex karyotype (ie more than one occurrence of disease progression in the first group is highly significant (P Ͻ 0.0001). When the ages of the patients with abnormality) was present in 18 patients, including seven who had deletion at 11q and six patients with abnormalities at 13q.
11q deletions were compared with the other patients there was no significant difference. Nine patients had three or more karyotypic abnormalities.
The median follow-up from diagnosis of CLL has been 96 months. Figure 1 ). The patients with del(11q) (12%) patients with chromosomal abnormality and Pittman and Catovsky 9 reported it in three of 33 (9%) evaluable were also compared with all other patients with abnormal karyotype (n = 32) and again there was significantly worse surpatients. Recently comparative genomic hybridisation (CGH) has demonstrated deletions of 11q in four of 28 (14%) patients vival (88 months vs 169 months, P = 0.0012; Figure 2 ). Full karyotype and clinical features of patients with del(11q) is (21% of those with CGH abnormality). This technique is particularly useful in detecting chromosomal losses and gains, and shown in Table 1 . There was a significantly worse survival in patients with complex karyotype showing three or more the four patients with 11q deletion had been missed with standard karyotypic analysis with G-banding. Previously most abnormalities when compared with normal karyotype (P = 0.024; Figure 3 ). There was no significant difference interest in 11q abnormalities in CLL has focused on t(11;14)(q13;q32); it is however increasingly clear that this when patients with one or two chromosomal abnormalities were compared with normal. abnormality is uncommon in typical CLL and that many past reports probably refer to cases of leukemic mantle cell lymWhen the stage at diagnosis was examined in patients with deletions at 11q nine patients were stage A, one stage B and phoma or prolymphocytic leukemia. The low rate of trisomy 12 in this study (2.3%) is a reflection that this karyotype is one stage C. In the remainder of the patients 45 were stage A, 10 stage B and five stage C. There was no significant differmore often seen in CLL with atypical morphology, 14 while the high incidence of 13q14 abnormalities support previous ence in the stage at diagnosis between the two groups. Disassociation of this with typical morphology in CLL. 15 We have shown that 13q14 abnormalities do not confer a worse prognosis, while complex karyotypic abnormalities with three or more abnormalities do have a poorer outlook, both when compared with normal. These data are entirely in keeping with previous studies.
2,10 This study shows that patients with karyotypic abnormalities involving del(11q) have a significantly worse prognosis than those with a normal or any other abnormal karyotype. Although this is a relatively small study, the patients were completely uniform in respect to morphology and immunophenotype and the follow-up is extremely long. Some may question the use of patients with normal karyotype as a comparison, as they may have undetected clonal chromosomal abnormalities. While we accept this, we still feel that from the practical angle this is still a (n = 11) and 13q14 abnormalities (n = 14) compared with those with useful comparison.
normal karyotype (n = 41). 13q vs normal (P = NS), del(11q) vs normal (P Ͻ 0.0001).
In the past the correlation of specific chromosomal abnor- patients with deletions at 11q23 and one at 11q21. However, in patients with CLL and 11q abnormalities, deletion of genomic region of 7-9 mbp proximal to the MLL gene has been identified which contains the genes for NCAM, PLFZ and ataxia telangiectasia. 19 Further clinical studies are required to confirm the clinical relevance of this finding in a larger number of patients in a prospective manner.
The routine use of cytogenetics in at least a proportion of patients with CLL is indicated. Consideration should also be given to more intensive therapy at an earlier stage in these patients.
